rss
Arch Dis Child 2009;94:224-226 doi:10.1136/adc.2007.125195
  • Short report

Henoch-Schönlein purpura and meningococcal B vaccination

  1. K Sexton1,
  2. A McNicholas1,
  3. Y Galloway1,
  4. S Radke1,
  5. C Kieft1,
  6. P Stehr-Green1,
  7. S Reid1,
  8. J Neutze2,
  9. R Drake3
  1. 1
    Meningococcal Vaccine Strategy, Ministry of Health, Wellington, New Zealand
  2. 2
    Middlemore Hospital, Manukau, New Zealand
  3. 3
    Auckland City Hospital, Auckland, New Zealand
  1. Anne McNicholas, Meningococcal Vaccine Strategy, Ministry of Health, PO Box 5013, Wellington, New Zealand; anne_mcnicholas{at}moh.govt.nz
  • Accepted 25 June 2008
  • Published Online First 23 July 2008

Abstract

The risk of Henoch-Schönlein purpura (HSP) following vaccination with a group B meningococcal vaccine was assessed through active hospital safety monitoring. There was no increase in the relative incidence of HSP within 30 days after vaccination nor recurrence in HSP cases who received one or more further vaccine doses (re-challenge).

Footnotes

  • Competing interests: Chiron Vaccines (now Novartis Vaccines and Diagnostics S.r.l.) funded the New Zealand Ministry of Health to undertake the safety monitoring.

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

ADC is co-owned by the RCPCH and is the official journal of the European Academy of Paediatrics